PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
5.62%
Some net income increase while AGEN is negative at -54.39%. John Neff would see a short-term edge over the struggling competitor.
3.20%
Some D&A expansion while AGEN is negative at -0.35%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
No Data
No Data available this quarter, please select a different quarter.
22.07%
SBC growth well above AGEN's 39.67%. Michael Burry would flag major dilution risk vs. competitor’s approach.
81.65%
Slight usage while AGEN is negative at -1027.92%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
50.82%
A yoy AP increase while AGEN is negative at -84.81%. John Neff would see competitor possibly improving relationships or liquidity more rapidly.
28.44%
Lower 'other working capital' growth vs. AGEN's 65.62%. David Dodd would see fewer unexpected short-term demands on cash.
-17.77%
Negative yoy while AGEN is 275.80%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
18.75%
Some CFO growth while AGEN is negative at -29.98%. John Neff would note a short-term liquidity lead over the competitor.
-1425.00%
Both yoy lines negative, with AGEN at -1058.16%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1425.00%
Both yoy lines negative, with AGEN at -1058.16%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
No Data
No Data available this quarter, please select a different quarter.
-0.29%
Both yoy lines negative, with AGEN at -84.97%. Martin Whitman suspects an environment or preference for internal financing over new equity in the niche.
No Data
No Data available this quarter, please select a different quarter.